In recent years, targeted drugs, including commonly applied receptor tyrosine kinase inhibitors (RTKi) and novel MEKi, have become valuable antitumor drugs for advanced or progressive thyroid cancer (Jin et al., 2018). Here, NTRK1 is linked to thyroid gland carcinoma.